Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

Journal of Experimental Medicine

Volumn 207, Issue 10, 2010, Pages 2127-2140

  Sarig, Rachel ^a   Rivlin, Noa ^a   Brosh, Ran ^a   Bornstein, Chamutal ^a   Kamer, Iris ^a   Ezra, Osnat ^a   Molchadsky, Alina ^a   Goldfinger, Naomi ^a   Brenner, Ori ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GERM LAYER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SOMATIC CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MUTATION; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; SOXB1 TRANSCRIPTION FACTORS;

EID: 77957748239     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20100797     Document Type: Article

References (57)

1. Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA. 100:3983-3988. doi:10.1073/pnas.0530291100
2. Amariglio, N., A. Hirshberg, B.W. Scheithauer, Y. Cohen, R. Loewenthal, L. Trakhtenbrot, N. Paz, M. Koren-Michowitz, D. Waldman, L. Leider-Trejo, et al. 2009. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6:e1000029. doi:10.1371/journal. pmed.1000029
3. Ben-Porath, I., M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, A. Regev, and R.A. Weinberg. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40:499-507. doi:10.1038/ng.127
4. Brosh, R., and V. Rotter. 2009. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer. 9:701-713.
5. Clark, A.T. 2007. The stem cell identity of testicular cancer. Stem Cell Rev. 3:49-59. doi:10.1007/s12015-007-0002-x
6. Evans, P.M., and C. Liu. 2008. Roles of Krüpel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim. Biophys. Sin. (Shanghai). 40:554-564. doi:10.1111/j.1745-7270.2008.00439.x
7. Foudah, D., S. Redaelli, E. Donzelli, A. Bentivegna, M. Miloso, L. Dalprà, and G. Tredici. 2009. Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res. 17:1025-1039. doi:10.1007/s10577-009-9090-6
8. Gidekel, S., G. Pizov, Y. Bergman, and E. Pikarsky. 2003. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 4:361-370. doi:10.1016/S1535-6108(03)00270-8 (Pubitemid 37491097)
9. Gu, G., J. Yuan, M. Wills, and S. Kasper. 2007. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67:4807-4815. doi:10.1158/0008-5472.CAN-06-4608
10. Hanahan, D., and R.A. Weinberg. 2000. The hallmarks of cancer. Cell. 100:57-70. doi:10.1016/S0092-8674(00)81683-9
11. Hanna, J., K. Saha, B. Pando, J. van Zon, C.J. Lengner, M.P. Creyghton, A. van Oudenaarden, and R. Jaenisch. 2009. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature. 462:595-601. doi:10.1038/nature08592
12. Hochedlinger, K., and K. Plath. 2009. Epigenetic reprogramming and induced pluripotency. Development. 136:509-523. doi:10.1242/dev.020867
13. Hochedlinger, K., Y. Yamada, C. Beard, and R. Jaenisch. 2005. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 121:465-477. doi:10.1016/j.cell.2005.02.018
14. Holland, A.J., and D.W. Cleveland. 2009. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10:478-487. doi:10.1038/nrm2718
15. Hong, H., K. Takahashi, T. Ichisaka, T. Aoi, O. Kanagawa, M. Nakagawa, K. Okita, and S. Yamanaka. 2009. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 460:1132-1135. doi:10.1038/ nature08235
16. Ivanova, N., R. Dobrin, R. Lu, I. Kotenko, J. Levorse, C. DeCoste, X. Schafer, Y. Lun, and I.R. Lemischka. 2006. Dissecting self-renewal in stem cells with RNA interference. Nature. 442:533-538. doi:10.1038/nature04915
17. Jaenisch, R., and R. Young. 2008. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 132:567-582. doi:10.1016/j.cell. 2008.01.015 (Pubitemid 351253686)
18. Josse, C., R. Schoemans, N.A. Niessen, M. Delgaudine, A.C. Hellin, C. Herens, P. Delvenne, and V. Bours. 2010. Systematic chromosomal aberrations found in murine bone marrow-derived mesenchymal stem cells. Stem Cells Dev. In press.
19. Kawamura, T., J. Suzuki, Y.V. Wang, S. Menendez, L.B. Morera, A. Raya, G.M. Wahl, and J.C. Belmonte. 2009. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 460:1140-1144. doi:10.1038/nature08311
20. Kim, C.F., and P.B. Dirks. 2008. Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell. 3:147-150. doi:10.1016/j.stem.2008.07.012
21. Kim, J.B., V. Sebastiano, G. Wu, M.J. Araúzo-Bravo, P. Sasse, L. Gentile, K. Ko, D. Ruau, M. Ehrich, D. van den Boom, et al. 2009. Oct4-induced pluripotency in adult neural stem cells. Cell. 136:411-419. doi:10.1016/j.cell. 2009.01.023
22. Knoepfler, P.S. 2009. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 27:1050-1056. doi:10.1002/stem.37
23. Kochupurakkal, B.S., R. Sarig, O. Fuchs, D. Piestun, G. Rechavi, and D. Givol. 2008. Nanog inhibits the switch of myogenic cells towards the osteogenic lineage. Biochem. Biophys. Res. Commun. 365:846-850. doi:10.1016/j.bbrc.2007.11. 073
24. Lang, G.A., T. Iwakuma, Y.A. Suh, G. Liu, V.A. Rao, J.M. Parant, Y.A. Valentin-Vega, T. Terzian, L.C. Caldwell, L.C. Strong, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 119:861-872. doi:10.1016/j.cell.2004.11.006
25. Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres- Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 367:645-648. doi:10.1038/367645a0
26. Lazebnik, Y. 2010. What are the hallmarks of cancer? Nat. Rev. Cancer. 10:232-233. doi:10.1038/nrc2827
27. Levine, A.J., and M. Oren. 2009. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer. 9:749-758. doi:10.1038/nrc2723
28. Li, H., M. Collado, A. Villasante, K. Strati, S. Ortega, M. Cañamero, M.A. Blasco, and M. Serrano. 2009. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 460:1136-1139. doi:10.1038/ nature08290
29. Lin, T., C. Chao, S. Saito, S.J. Mazur, M.E. Murphy, E. Appella, and Y. Xu. 2005. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol. 7:165-171. doi: 10.1038/ncb1211
30. Maherali, N., and K. Hochedlinger. 2008. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 3:595-605. doi:10.1016/j.stem.2008.11.008
31. Maimets, T., I. Neganova, L. Armstrong, and M. Lako. 2008. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene. 27:5277-5287. doi:10.1038/onc.2008.166
32. Malkin, D., F.P. Li, L.C. Strong, J.F. Fraumeni Jr., C.E. Nelson, D.H. Kim, J. Kassel, M.A. Gryka, F.Z. Bischoff, M.A. Tainsky, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1233-1238. doi:10.1126/science.1978757
33. Marión, R.M., K. Strati, H. Li, M. Murga, R. Blanco, S. Ortega, O. Fernandez-Capetillo, M. Serrano, and M.A. Blasco. 2009. A p53- mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 460:1149-1153. doi:10.1038/nature08287
34. Masui, S., Y. Nakatake, Y. Toyooka, D. Shimosato, R. Yagi, K. Takahashi, H. Okochi, A. Okuda, R. Matoba, A.A. Sharov, et al. 2007. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat. Cell Biol. 9:625-635. doi:10.1038/ncb1589
35. Matas, D., M. Milyavsky, I. Shats, L. Nissim, N. Goldfinger, and V. Rotter. 2004. p53 is a regulator of macrophage differentiation. Cell Death Differ. 11:458-467. doi:10.1038/sj.cdd.4401379
36. Molchadsky, A., I. Shats, N. Goldfinger, M. Pevsner-Fischer, M. Olson, A. Rinon, E. Tzahor, G. Lozano, D. Zipori, R. Sarig, and V. Rotter. 2008. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 3:e3707. doi:10.1371/journal.pone.0003707
37. Okita, K., T. Ichisaka, and S. Yamanaka. 2007. Generation of germline-competent induced pluripotent stem cells. Nature. 448:313-317. doi:10.1038/nature05934 (Pubitemid 47080336)
38. Olive, K.P., D.A. Tuveson, Z.C. Ruhe, B. Yin, N.A. Willis, R.T. Bronson, D. Crowley, and T. Jacks. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 119:847-860. doi:10.1016/j.cell.2004.11.004
39. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414:105-111. doi:10.1038/35102167
40. Rowland, B.D., R. Bernards, and D.S. Peeper. 2005. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7:1074-1082. doi:10.1038/ncb1314
41. Sarig, R., V. Mezger-Lallemand, I. Gitelman, C. Davis, O. Fuchs, D. Yaffe, and U. Nudel. 1999. Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development. Hum. Mol. Genet. 8:1-10. doi:10.1093/hmg/8.1.1
42. Sarig, R., Z. Baruchi, O. Fuchs, U. Nudel, and D. Yaffe. 2006. Regeneration and transdifferentiation potential of muscle-derived stem cells propagated as myospheres. Stem Cells. 24:1769-1778. doi:10.1634/stemcells.2005- 0547
43. Sell, S. 2004. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51:1-28. doi:10.1016/j.critrevonc.2004.04.007
44. Shaulsky, G., N. Goldfinger, and V. Rotter. 1991. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51:5232-5237.
45. Srivastava, S., Z.Q. Zou, K. Pirollo, W. Blattner, and E.H. Chang. 1990. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 348:747-749. doi:10.1038/348747a0 (Pubitemid 120015153)
46. Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663-676. doi:10.1016/j.cell.2006.07.024
47. Taussig, D.C., D.J. Pearce, C. Simpson, A.Z. Rohatiner, T.A. Lister, G. Kelly, J.L. Luongo, G.A. Danet-Desnoyers, and D. Bonnet. 2005. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 106:4086-4092. doi:10.1182/blood-2005-03-1072
48. Terzian, T., Y.A. Suh, T. Iwakuma, S.M. Post, M. Neumann, G.A. Lang, C.S. Van Pelt, and G. Lozano. 2008. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22:1337-1344. doi:10.1101/gad.1662908
49. Tolar, J., A.J. Nauta, M.J. Osborn, A. Panoskaltsis Mortari, R.T. McElmurry, S. Bell, L. Xia, N. Zhou, M. Riddle, T.M. Schroeder, et al. 2007. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 25:371-379. doi:10.1634/stemcells.2005-0620
50. Utikal, J., J.M. Polo, M. Stadtfeld, N. Maherali, W. Kulalert, R.M. Walsh, A. Khalil, J.G. Rheinwald, and K. Hochedlinger. 2009. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 460:1145-1148. doi:10.1038/nature08285
51. Viswanathan, S.R., J.T. Powers, W. Einhorn, Y. Hoshida, T.L. Ng, S. Toffanin, M. O'Sullivan, J. Lu, L.A. Phillips, V.L. Lockhart, et al. 2009. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41:843-848. doi:10.1038/ng.392
52. Wang, Y., J. Yang, H. Zheng, G.J. Tomasek, P. Zhang, P.E. McKeever, E.Y. Lee, and Y. Zhu. 2009. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell. 15:514-526. doi:10.1016/j.ccr.2009.04.001
53. West, J.A., S.R. Viswanathan, A. Yabuuchi, K. Cunniff, A. Takeuchi, I.H. Park, J.E. Sero, H. Zhu, A. Perez-Atayde, A.L. Frazier, et al. 2009. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature. 460:909-913.
54. Wilmut, I., A.E. Schnieke, J. McWhir, A.J. Kind, and K.H. Campbell. 1997. Viable offspring derived from fetal and adult mammalian cells. Nature. 385:810-813. doi:10.1038/385810a0 (Pubitemid 27106068)
55. Yamanaka, S. 2009. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 460:49-52. doi:10.1038/nature08180
56. Yewdell, J.W., J.V. Gannon, and D.P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444-452. (Pubitemid 16013993)
57. Zhao, Y., X. Yin, H. Qin, F. Zhu, H. Liu, W. Yang, Q. Zhang, C. Xiang, P. Hou, Z. Song, et al. 2008. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 3:475-479. doi:10.1016/j.stem.2008.10.002